UNSPSC 51434813: Peraquinsin

This classification denotes an antihypertensive agent with the molecular formula C23H28N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5726CF21KY, chemically known as 6,7-dimethoxy-2-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-4-(3h)-quinazolinone but generally known as peraquinsin, which bears US NIH Compound Identifier 3047831. European Medicines Agency schedules Peraquinsin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09714MIG.

UNSPSC 51434813 Peraquinsin, a Commodity code, encompasses pharmaceutical products and related medications procured by state and local health agencies, fire departments, and multistate cooperative purchasing consortia for emergency medical services, pharmacy benefit programs, and institutional healthcare delivery. State and local governments acquire these medications through sealed competitive bidding processes targeting emergency life support inventories and through cooperative purchasing frameworks that aggregate demand across multiple jurisdictions and administrative entities. Issuing bodies include municipal fire departments (City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The work entails supplying pharmaceuticals with strict compliance requirements around expiration dating, shelf life, cold-chain management where applicable, manufacturing certifications (cGMP, DSCSA), FDA approval, safety data sheets, and accessibility documentation (WCAG 2.2, Section 508 standards). Contracts typically run one to two years with renewal or extension options negotiated at issuing-body discretion.

Recent activity spans Texas, Minnesota, Florida, and Oregon. The City of Tampa's Fire Rescue division issued IFB 26P00188 in April 2026 for advanced life support medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, subject to a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract commencement July 1, 2026; this RFP emphasizes price competitiveness (75 percent weighting), manufacturer certification, and distribution through three authorized wholesalers. The Texas HHS Commission issued RFI HHS0017013 in March 2026 seeking vendor input on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization arrangements—a preliminary market-intelligence phase preceding formal procurement.